Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, we have a portfolio of commercially-available PLAC® Tests, the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

May 23, 2016

Diadexus, Inc. and Sonic Healthcare USA Sign National Agreement for PLAC(R) Activity Test

Apr 28, 2016

Diadexus, Inc. Reports First Quarter 2016 Financial Results